Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P62988 (
Ubiquitin
)
4,326
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Ubiquitin carboxyl-terminal hydrolase 37
(UCH37, also called UCHL5), a member of the deubiquitinating enzymes, can suppress protein degradation through disassembling
polyubiquitin
from the distal subunit of the chain. It has been proved that UCH37 can be activated by proteasome ubiqutin chain receptor Rpn13 and incorporation into the 19S complex. UCH37, which has been reported to assist in the mental development of mice, may play an important role in oncogenesis, tumor invasion and migration. Further studies will allow a better understanding of roles in cell physiology and pathology, embryonic development and tumor formation, hopefully providing support for the idea that UCH37 may constitute a new interesting target for the development of anticancer drugs.
...
PMID:Power and promise of ubiquitin carboxyl-terminal hydrolase 37 as a target of cancer therapy. 2372 8
Ubiquitin carboxyl-terminal hydrolase 37
(
UCH37
) is a member of deubiquitinating enzymes. It can suppress protein degradation through disassembling
polyubiquitin
from the distal subunit of the chain. The aim of this study was to assess the value of
UCH37
in predicting tumor recurrence after curative resection in epithelial ovarian cancer (EOC) patients. In this study, the expression level of
UCH37
in 5 paired EOC and normal tissue was tested by Western blot. And the association of
UCH37
expression and prognostic value was analyzed in 100 tumor specimens from EOC patients, who underwent curative resection between 2003 and 2011. We found that
UCH37
was up-regulated in most of the tumor tissue and high expression of
UCH37
was an independent significant predictor associated with the poor outcome and recurrence of EOC (p=0.0037 and p=0.0042 in overall and disease-free survival, respectively), especially in the advanced stage of EOC (p=0.0106 and p=0.0115 in overall and disease-free survival, respectively), and may become a novel predictor for prognosis of EOC patients after curative resection. Our data suggest for the first time that
UCH37
overexpression is associated with advanced tumor progression and poor clinical outcome of EOC patients and may help physicians make informed decisions regarding adjuvant treatment following curative resection.
...
PMID:High expression of UCH37 is significantly associated with poor prognosis in human epithelial ovarian cancer. 2512 64